WFH Statements and Advisories
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
-
Alert on the use of vials of water for injection (2.5ml, 5ml and 10ml) included in some LFB BIOMEDICAMENTS products
Please note that LFB BIOMEDICAMENTS has issued an alert concerning a defect in the quality appearance of the water for injection (vials 2.5ml, 5ml and...
-
Update from Roche on Hemlibra (emicizumab)
Update from Roche on Hemlibra (emicizumab), for more information please click here.
-
Update: FDA lifts suspension of Fitusiran trial
The United States Food and Drug Administration has agreed to allow Alnylam’s clinical trial of the novel drug Fitusiran to resume. The FDA and Alnylam...
-
FDA approves Hemlibra for treatment of hemophilia A with inhibitors
Roche has announced that the U.S.A Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for the treatment of hemophilia A with inhibitors. This approval...
-
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event in Phase 2 open-label extension study
The WFH was saddened to learn of the death of a hemophilia A patient taking part in the Phase II trial of fitusiran, in development...
-
Roche statement on emicizumab clinical trial adverse event
Roche has released the following statement to the WFH following the death of a patient in a clinical trial. The WFH expresses our sincere condolences...
-
WFH STATEMENT on SIPPET Study Results
The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published May 26, 2016 in the New England Journal of Medicine....
-
SIPPET study results published in New England Journal of Medicine
May, 2016 – The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published today in the New England Journal of...
